Linzess Approved for Pediatric IBS-C: A New Hope for Families
Update: 2025-11-05
Description
**Summary:**Ironwood Pharmaceuticals' stock surged by eight percent on November fifth following the FDA's approval of Linzess capsules for children aged seven and older with IBS-C. This marks a significant milestone as Linzess is now the first treatment specifically approved for pediatric IBS-C patients. The approval was based on positive results from a twelve-week clinical trial, with the recommended dosage being one hundred forty-five micrograms once a day. The drug is not suitable for children under two or those with gastrointestinal obstruction.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
